Andreas Hochhaus, MD, discusses results from a phase I study suggesting asciminib may have superior efficacy to bosutinib in patients with heavily pretreated chronic myeloid leukemia.
Andreas Hochhaus, MD, discusses results from a phase I study suggesting asciminib may have superior efficacy to bosutinib in patients with heavily pretreated chronic myeloid leukemia.